Supercede Therapeutics is focused on developing innovative therapeutics that target biological pathways associated with various human diseases. The company employs advanced bioinformatics, including artificial intelligence and machine learning, to enhance the efficiency of drug discovery processes. This approach allows Supercede to streamline clinical development strategies, ensuring that new treatments reach patients more quickly. Their pipeline includes therapeutic compounds aimed at clinically validated targets across a range of conditions, including renal, metabolic, and neurological diseases.

The lead program, STX-001, is an oral small molecule inhibitor of the Activin receptor Type II (ACTRII) kinase, currently in preclinical development for obesity treatment. This compound has demonstrated the ability to significantly reduce fat while promoting an increase in lean body mass, addressing a critical need in obesity management. Supercede's commitment to integrating cutting-edge bioinformatics throughout the drug discovery process aims to answer essential questions regarding the safety, biological activity, and clinical benefits of their new drugs, ultimately enhancing the therapeutic landscape for patients in need.

United States

Supercede Therapeutics develops novel therapeutics targeting biological pathways relevant to human disease. We apply bioinformatics (AI/ML) to make drug discovery more efficient and effective.

Supercede Therapeutics

Company Details